Tremfya
IL-23 blockade with long dosing intervals and durable psoriasis clearance.
Tremfya (guselkumab) inhibits interleukin-23, the signal upstream of the inflammatory cascade in psoriasis. For plaque psoriasis, this targeted pathway can support sustained control with maintenance dosing commonly given every eight weeks after loading. Schedules vary by indication and prescribing guidance.
- Injection
- Route
- 8 weekly
- Interval
- 4–16 wks
- First results
- IL-23
- Target
- Baseline screening
- Week 0 and 4 loading
- 8-weekly maintenance
- Photographic monitoring
Diagnosed first, treated second.
It suits patients with stubborn plaques, scalp or nail involvement, and those who have cycled through other systemics. Response is measured objectively, and continuation depends on documented improvement rather than impression.
- 01Baseline screening
- 02Week 0 and 4 loading
- 038-weekly maintenance
- 04Photographic monitoring
- 05Severity scoring
- Moderate to severe plaque psoriasis
- Failure or intolerance of other biologics
- Difficult scalp or nail involvement
- Preference for infrequent dosing
- Cleared infection screening
How the treatment works
A sequence, not a single appointment — each step informs the next.
- 01
Assessment
Plaque distribution, nail and scalp involvement, joint symptoms and quality-of-life scoring.
- 02
Screening
Infection screening and baseline laboratory work before the first injection.
- 03
Loading
Doses at week zero and week four to establish therapeutic levels quickly.
- 04
Maintenance
One injection every eight weeks, reviewed at defined intervals with photographic records.
Results measured, not promised.
What to expect
- 01A meaningful chance of clear or almost-clear skin
- 02Improvement in scalp and nail disease
- 03Only six injections a year on maintenance
- 04Response may be sustained with ongoing therapy
- 05Reduced flare frequency and severity
Results, treatment timing and recovery vary by diagnosis and individual factors. This page is educational and does not replace a medical consultation or guarantee an outcome. Prescription treatment is selected after reviewing current product information, approved indications, infection and vaccination history, other medicines and drug-specific risks.
Begin with a diagnosis,
not a guess.
Share a few details and the clinic will reply with available consultation times for tremfya — one-to-one with Dr. Arely.
- Response
- Within 24 hours
- Consultation
- One-to-one, 45 min
- Assessment
- Trichoscopy included
- Location
- Dr. Arely Clinic
Frequently asked
It targets IL-23 rather than IL-17. The practical differences include dosing schedule, approved indications and individual safety considerations; choice is made clinically.
Yes, it is effective in psoriatic arthritis alongside skin disease.
Reviews at week four, week sixteen and then every three to six months once stable.
Yes. Short courses of topical therapy are often used for residual areas.